ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

  • March 3, 2016

Rockville, MD – March 3, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.

The award is an indefinite delivery/indefinite quantity (IDIQ) contract with a 5-year base period of performance plus five one-year options, and a total contract value of $900 million for all awardees, if all options are exercised.

As a member of the Engility team, ABL will have the opportunity to apply its comprehensive project management, product development, GMP manufacturing, and testing services in support of medical product research to support the Nation’s military.

Thomas VanCott, Ph.D., ABL’s President and CEO said, “The required breadth of product development expertise for the scope of this contract lies within ABL’s core competency. With over 50 years of experience conducting biomedical research, as well as manufacturing vaccines and therapeutics for the U.S. Government, ABL provides a unique combination of scientific expertise coupled with operational excellence to address the complex medical issues facing our military today.”  Dr. VanCott continued, “ABL has a proven track record of rapidly assessing highly technical projects and bringing together the right mix of in-house capabilities and external resources to complete mission objectives, and we look forward to contributing to the advancement of critical medical research and products required by the Army and other Department of Defense entities.”

About ABL

ABL, Inc. is a global biomedical contract research and manufacturing organization dedicated to advancing vaccines, therapeutics and other biologic products. ABL has extensive experience working with diverse organizations, including biopharmaceutical companies, government and academic entities. Notable cGMP manufacturing services for protein and virus products include process and assay development,  Phase I/II cGMP biologics manufacturing of bulk drug substance, cGMP aseptic fill and finish of drug product, and QC analytics.  ABL also maintains immunological and molecular laboratories to support preclinical and GCLP clinical sample processing and testing. ABL is a part of the Institut Mérieux, a group of companies dedicated to developing translational science for better patient care globally. For more information on ABL and our services, please visit our website at www.ablinc.com.